AzTrials
AzTrials

Transplant-Related DisorderNCT06393660

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

A study testing CliniMACS® CD34 TCR Alpha/Beta in people with Transplant-Related Disorder and GVH - Graft Versus Host Reaction, run by University of Texas Southwestern Medical Center at 1 site in United States.

Available

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The protocol is designed to provide access to patients to the Clinimacs® CD34 TCRαβ system to prepare cells for an unlabeled indication using an HLA-compatible related or unrelated donor for allogenic transplant. Read more about this study

Who is it for?
Ages Up to 21 years
What is being tested?
CliniMACS® CD34 TCR Alpha/Beta
Type of treatment
Medical device
How many people
Not given
Where
1 siteUnited States
Study dates
Start not givento not given
Phase
Expanded access
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 21 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Recipient Inclusion Criteria:

  • Age less than 22 years of age
  • No available genotypically matched related donor (sibling)
  • Availability of a suitable donor and graft source
  • Haploidentical related mobilized peripheral blood cells
  • 9/10 or 10/10 allele matched (HLA-A, -B, -C, -DRB1, -DQB1) volunteer unrelated donor mobilized peripheral blood cells

Donor Inclusion Criteria:

  • Matching as described in the Recipient and Donor Suitability Criteria
  • Size and vascular access appropriate by center standard for peripheral blood stem cell (PBSC) collection. Donors with inadequate peripheral access will require placement of an apheresis catheter for collection.
  • Must meet appropriate screening/eligibility requirements:
  • Haploidentical matched family members: screened by center health screens and found to be eligible.
  • Unrelated donors: meet suitability criteria to donate PBSC
  • HIV negative
  • Not pregnant or lactating
  • Recipient must not have high-level donor specific anti-HLA antibodies according to institutional practices.
  • Must agree to donate PBSC
  • Must give informed consent

Recipient Suitability:

  • Adequate organ functioning as demonstrated by:
  • MUGA ≥ 50% or ECHO \>30%
  • 24-hour Creatinine Clearance or Glofil ≥ 50 ml/min or Serum Creatinine ≤2 times the upper limit of normal
  • DLCO \> 65% of predicted value. FEV1 \>65% of predicted
  • AST / ALT ≤ 2.5 and/or Bilirubin ≤ 1.5 times the upper limit of normal
  • Pregnancy test negative
  • HIV 1 / 2 (HIV screen) negative with a negative qualitative HIV PCR.
  • HTLV I negative
  • RPR or VDRL negative
  • RVP (Respiratory Viral PCR) with a negative result
  • Positive hepatitis testing does not make the patient ineligible. Hepatitis results will be evaluated on a case-by-case basis by the transplant physician to determine donor suitability/eligibility.

Donor Suitability:

  • Allowed Donor Sources
  • Fully matched sibling donors are not allowed.
  • Unrelated donors. HLA typing of at least 10 alleles is required. Donor must be matched at 9/10 or 10/10 alleles (HLA-A, -B, -C, -DRB1, -DQB1). Haploidentical matched family members. Minimum match level full haploidentical (at least 5/10; HLA-A, -B, -C, -DRB1, -DQB1 alleles), but use of haploidentical donors with extra matches (e.g., 6, 7, or 8/10) encouraged.
  • Cord blood is not allowed as a stem cell source on this IDE.

Recipient and Donor Exclusion Criteria:

  • Pregnant or lactating females are ineligible as the risk to unborn children and infants is unknown
  • Presence of life-threatening, uncontrolled opportunistic infection (fungal, bacterial, or viral infections). Patients with history of fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT evaluation.
  • HIV or HTLV I/II infection

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Children's Medical Center - Dallas

    Dallas, Texas, 75235

    Victor Aquino, MD, 214-456-2382, Victor.Aquino@utsouthwestern.edu

    Available

Other trials in United States

About this study

Official title: Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta to Prepare Cells for an Unlabeled Indication Using an HLA-Compatible Related or Unrelated Donor for Allogenic Transplant

The protocol is designed to provide access to patients to the Clinimacs® CD34 TCRαβ system to prepare cells for an unlabeled indication using an HLA-compatible related or unrelated donor for allogenic transplant.

Read the detailed description

Allogeneic hematopoietic stem cell transplant (HSCT) is the only known curative therapy for a variety of non-malignant and malignant disorders1-4. Only about 25% of patients have an HLA-matched sibling and in about 16-75% (depending on ethnicity), a 10/10 HLA-matched unrelated donor can be identified. Engraftment failure is a dynamic complex process that may occur with this product due to unbalanced depletion of T-cells between recipient and donor, not only due to low number of CD34 cells. The use of mis-matched or haploidentical donors is associated with a higher risk of post-transplant mortality due to the development of severe graft versus host disease, graft failure and the development of infection due to the use of immunosuppression or T cell depletion. A total of 10 patients will be enrolled. The patients will be divided into 2 strata (haploidentical 7, unrelated donor 3).

Being tested
CliniMACS® CD34 TCR Alpha/Beta
Keywords
TCR Alpha/Beta, CliniMACS

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CliniMACS® CD34 TCR Alpha/BetaDevice

    CliniMACS System uses an automated antibody/magnetic beads column system that allows efficient depletion of TCRαβ and CD19+ cells without relevant loss of cell viability. Hematopoietic stem cells are retained in sufficient numbers to permit engraftment and hematopoietic reconstitution. Humanitarian Exemption IDE approval has been obtained for CD34+ cell selection as a method of T-cell depletion.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Expanded access
IDs, dates and publications
ClinicalTrials.gov ID
NCT06393660
Sponsor's protocol ID
STU-2024-0185
Status last verified
Oct 2026
First submitted
9 Apr 2024
Last updated
2 Nov 2026
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing CliniMACS® CD34 TCR Alpha/Beta in people with Transplant-Related Disorder and GVH - Graft Versus Host Reaction, run by University of Texas Southwestern Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Victor Aquino, MD (214-648-3896, Victor.Aquino@utsouthwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in